1. Home
  2. UA vs CPRX Comparison

UA vs CPRX Comparison

Compare UA & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Under Armour Inc. Class C

UA

Under Armour Inc. Class C

HOLD

Current Price

$5.98

Market Cap

3.4B

ML Signal

HOLD

Logo Catalyst Pharmaceuticals Inc.

CPRX

Catalyst Pharmaceuticals Inc.

HOLD

Current Price

$23.61

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UA
CPRX
Founded
1996
2002
Country
United States
United States
Employees
14400
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.0B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
UA
CPRX
Price
$5.98
$23.61
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$35.00
AVG Volume (30 Days)
2.4M
1.0M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.24
EPS
N/A
1.68
Revenue
N/A
$119,072,803.00
Revenue This Year
N/A
$9.20
Revenue Next Year
$1.72
$10.51
P/E Ratio
N/A
$13.51
Revenue Growth
N/A
16.39
52 Week Low
$3.95
$19.05
52 Week High
$7.91
$26.56

Technical Indicators

Market Signals
Indicator
UA
CPRX
Relative Strength Index (RSI) 40.53 49.38
Support Level $5.88 $22.25
Resistance Level $6.44 $24.94
Average True Range (ATR) 0.26 0.66
MACD -0.11 -0.12
Stochastic Oscillator 22.63 45.57

Price Performance

Historical Comparison
UA
CPRX

About UA Under Armour Inc. Class C

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Share on Social Networks: